Knowledge, Attitude and Perception of Physicians towards Adverse Drug Reaction Reporting at King Khalid University Hospital, Riyadh, Saudi Arabia

Purpose: To assess the knowledge and attitudes of physicians towards adverse drug reaction (ADR) reporting at King Khalid University Hospital, Riyadh, Saudi Arabia.Method: The study was conducted in King Khalid University Hospital (KKUH), Riyadh, Saudi Arabia over a three-month period (April to June 2014). A  self-administered questionnaire was delivered to 116 physicians. The questionnaire comprised of close-ended as well as open-ended questions. Descriptive  statistics including, frequency distribution and percentages, were used for both demographic data and various responses to the questions.Results: The response rate was 81.09 %. The mean age of the respondents was 33.3 ± 11.49 years. Of the 94 physicians who completed the questionnaire, 88.7 % of them didn’t know about the National  Pharmacovigilance Center. Almost all the physicians (95.7 %) were not satisfied by their training in ADRs reporting while half (49.3 %) of the respondents thought that only serious ADRs should be reported.Conclusion: There is a need for more educational and training programs for physicians regarding the pharmacovigilance system and ADRs reporting. More  research is needed to study the knowledge and attitudes of other healthcare professionals and in various settings.Keywords: Health care providers, Pharmacovigilance, Adverse drug reactions, Reporting, Knowledg

Attitudes and Perceptions of Healthcare Providers towards Clinical Pharmacy Services at a Tertiary Care Hospital in Riyadh, Saudi Arabia

Purpose: To evaluate the attitudes and perceptions of health care providers towards clinical pharmacy services at King Khalid University Hospital Riyadh Saudi ArabiaMethod: A cross-sectional survey of healthcare providers was conducted in King Khalid University Hospital, Riyadh, Saudi Arabia from September to November 2013. A self-administered questionnaire was delivered to health care professionals (HCPs) who included physicians, pharmacists and nurses.Results: The response rate was 78 % (457/600). The majority of the respondents (92.4 %) knew that the clinical pharmacist is an integral part of the medical team while 86.5 % of the participants expressed confidence in the ability of clinical pharmacists to improve the quality of patient care through their practice. Despite the relative lack of awareness of the increasing interest in clinical pharmacy practice (59.6 % were not aware of such a trend), pharmacists were less appreciative (p < 0.05) of the positive role of clinical  pharmacists in direct patient care compared to both physicians and nurses (67.4, 74.3 and 72.3 %, respectively).Conclusion: The findings of this study reveal that health care professionals HCPs have positive attitude towards the role of the clinical pharmacist in the health care setting studied. However, there is a need for Saudi hospitals to adopt full clinical pharmacy service including drug monitoring, drug information and pharmacotherapy for enhanced health care.Keywords: Saudi Arabia, Clinical pharmacy services, Healthcare professionals, Attitude, Patient car

Internal dose assessment of 210Po using biokinetic modeling and urinary excretion measurement

The mysterious death of Mr. Alexander Litvinenko who was most possibly poisoned by Polonium-210 (210Po) in November 2006 in London attracted the attention of the public to the kinetics, dosimetry and the risk of this high radiotoxic isotope in the human body. In the present paper, the urinary excretion of seven persons who were possibly exposed to traces of 210Po was monitored. The values measured in the GSF Radioanalytical Laboratory are in the range of natural background concentration. To assess the effective dose received by those persons, the time-dependence of the organ equivalent dose and the effective dose after acute ingestion and inhalation of 210Po were calculated using the biokinetic model for polonium (Po) recommended by the International Commission on Radiological Protection (ICRP) and the one recently published by Leggett and Eckerman (L&E). The daily urinary excretion to effective dose conversion factors for ingestion and inhalation were evaluated based on the ICRP and L&E models for members of the public. The ingestion (inhalation) effective dose per unit intake integrated over one day is 1.7 × 10−8 (1.4 × 10−7) Sv Bq−1, 2.0 × 10−7 (9.6 × 10−7) Sv Bq−1 over 10 days, 5.2 × 10−7 (2.0 × 10−6) Sv Bq−1 over 30 days and 1.0 × 10−6 (3.0 × 10−6) Sv Bq−1 over 100 days. The daily urinary excretions after acute ingestion (inhalation) of 1 Bq of 210Po are 1.1 × 10−3 (1.0 × 10−4) on day 1, 2.0 × 10−3 (1.9 × 10−4) on day 10, 1.3 × 10−3 (1.7 × 10−4) on day 30 and 3.6 × 10−4 (8.3 × 10−5) Bq d−1 on day 100, respectively. The resulting committed effective doses range from 2.1 × 10−3 to 1.7 × 10−2 mSv by an assumption of ingestion and from 5.5 × 10−2 to 4.5 × 10−1 mSv by inhalation. For the case of Mr. Litvinenko, the mean organ absorbed dose as a function of time was calculated using both the above stated models. The red bone marrow, the kidneys and the liver were considered as the critical organs. Assuming a value of lethal absorbed dose of 5 Gy to the bone marrow, 6 Gy to the kidneys and 8 Gy to the liver, the amount of 210Po which Mr. Litvinenko might have ingested is therefore estimated to range from 27 to 1,408 MBq, i.e 0.2–8.5 μg, depending on the modality of intake and on different assumptions about blood absorption

Association between exposure to environmental tobacco smoke and biomarkers of oxidative stress among patients hospitalised with acute myocardial infarction

Objective To determine whether exposure to environmental tobacco smoke was associated with oxidative stress among patients hospitalised for acute myocardial infarction.<p></p> Design An existing cohort study of 1,261 patients hospitalised for acute myocardial infarction.<p></p> Setting Nine acute hospitals in Scotland.<p></p> Participants Sixty never smokers who had been exposed to environmental tobacco smoke (admission serum cotinine ≥3.0 ng/mL) were compared with 60 never smokers who had not (admission serum cotinine ≤0.1 ng/mL).<p></p> Intervention None.<p></p> Main outcome measures Three biomarkers of oxidative stress (protein carbonyl, malondialdehyde (MDA) and oxidised low-density lipoprotein (ox-LDL)) were measured on admission blood samples and adjusted for potential confounders.<p></p> Results After adjusting for baseline differences in age, sex and socioeconomic status, exposure to environmental tobacco smoke was associated with serum concentrations of both protein carbonyl (beta coefficient 7.96, 95% CI 0.76, 15.17, p = 0.031) and MDA (beta coefficient 10.57, 95% CI 4.32, 16.81, p = 0.001) but not ox-LDL (beta coefficient 2.14, 95% CI −8.94, 13.21, p = 0.703).<p></p> Conclusions Exposure to environmental tobacco smoke was associated with increased oxidative stress. Further studies are requires to explore the role of oxidative stress in the association between environmental tobacco smoke and myocardial infarction.<p></p&gt

Community pharmacists attitudes towards mental illness and providing pharmaceutical care for mentally ill patients.

To examine the attitudes of community pharmacist to both mental illness and provision of pharmaceutical care. METHODS: The study was conducted from May 2006 to September 2006 in College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. The survey composed of the demographic characteristics of the respondents, who were asked 6 Likert type questions on the attitudes of the pharmacists toward mental illness, providing pharmaceutical care to mentally ill patients, the barriers of the provision of the service and differentiation between different types of mental illness. RESULTS: Forty-three pharmacists participated in the study. Eighty-eight percent of the pharmacists felt that mental illness was the same as other illnesses. Sixty-six percent of the respondents "strongly agree," or "agree" that mentally ill patients were easily recognizable. Thirty-three percent of the respondents "disagree," or "strongly disagree" that mentally ill patients have no ability to tell right from wrong. In general, 43.3-87.7% of respondents are being "much more" or "more" interested, comfortable, and confident to perform pharmaceutical care to mentally ill patients. An average range of 30-67% of respondents felt neutral, or "much more" or "more" comfortable, confident for screening and solving drug-related problems, and compliance with drug therapy. Barriers that limit the provision of pharmaceutical care to the mentally ill patients include the lack of training in pharmaceutical care practice (88.4%), lack of therapeutic knowledge (83.7%), lack of documentation skill (79%), lack of communication (76.8%), lack of space for counseling (76.7%), insufficient time (74.5%) and lack of staff (72.1%). CONCLUSION: Although pharmacists have positive attitudes to both mental illness and providing pharmaceutical care to mentally ill patients, they felt uncomfortable counseling or carrying out follow-up monitoring of patients for adverse drug-related problems

Clinical Knowledge, Attitude, and Perceptions of Community Pharmacists Towards Pharmacogenomics - A Cross-Sectional Study from Saudi Arabia

Ziyad Alrabiah, Wajid Syed, Salmeen D Babelghaith, Mohamed N Al Arifi Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi ArabiaCorrespondence: Wajid Syed, Email [email protected] and Aims: It is crucial to provide healthcare personnel with the necessary knowledge and understanding of genetic testing and pharmacogenomics. The purpose of this study is to assess the knowledge, attitudes, views, and considerations of Community pharmacists (CPs) about pharmacogenomics and genetics.Methods and Materials: A cross-sectional web-based study was conducted among practicing pharmacists Between January and February of 2022. Participants were recruited through a convenient sampling technique. A total of 23 item questionnaires were used to assess the Knowledge Attitudes, Views, and Considerations toward Pharmacogenomics among pharmacists.Results: The mean age of the CPs were 28.45± 7.29(Std). Among the CPs, 38.4% (98 of 255) of them were correctly identified human chromosomes, and the majority of them 73.3% knew that adverse reactions can be caused by genetic changes in the human body. A total of 194 CPs agreed that certain drugs can be affected by genetic changes in the patient. In this study, one-third (33%) of the CPs were found to have good knowledge, while most (66.3%) of the CPs were found poor knowledge of pharmacogenomics and genetics. Furthermore, the knowledge score is significantly different concerning the qualification of the CPs (p=0.0001).Conclusion: The current findings, demonstrated a majority of the CPs found a lack of knowledge and understanding regarding pharmacogenomics and its perspectives, there is a need to increase awareness among CPs to reduce the knowledge gap of pharmacogenomics and genetics.Keywords: community pharmacist, pharmacogenomics, chromosomes, genetic change